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Abstract
ADAM10, as the sheddase of the low affinity IgE receptor (CD23), promotes IgE production
and thus is a unique target for attenuating allergic disease. Herein, we describe that B cell
levels of ADAM10, specifically, are increased in allergic patients and Th2 proneWT mouse
strains (Balb/c and A/J). While T cell help augments ADAM10 expression, Balb WT B cells
exhibit increased ADAM10 in the naïve state and even more dramatically increased
ADAM10 after anti-CD40/IL4 stimulation compared C57 (Th1 prone) WT B cells. Further-
more, ADAM17 and TNF are reduced in allergic patients and Th2 prone mouse strains
(Balb/c and A/J) compared to Th1 prone controls. To further understand this regulation,
ADAM17 and TNF were studied in C57Bl/6 and Balb/c mice deficient in ADAM10. C57-
ADAM10B-/- were more adept at increasing ADAM17 levels and thus TNF cleavage result-
ing in excess follicular TNF levels and abnormal secondary lymphoid tissue architecture not
noted in Balb-ADAM10B-/-. Moreover, the level of B cell ADAM10 as well as Th context is
critical for determining IgE production potential. Using a murine house dust mite airway
hypersensitivity model, we describe that high B cell ADAM10 level in a Th2 context (Balb/c
WT) is optimal for disease induction including bronchoconstriction, goblet cell metaplasia,
mucus, inflammatory cellular infiltration, and IgE production. Balb/c mice deficient in B cell
ADAM10 have attenuated lung and airway symptoms compared to Balb WT and are actual-
ly most similar to C57 WT (Th1 prone). C57-ADAM10B-/- have even further reduced sympto-
mology. Taken together, it is critical to consider both innate B cell levels of ADAM10 and
ADAM17 as well as Th context when determining host susceptibility to allergic disease.
High B cell ADAM10 and low ADAM17 levels would help diagnostically in predicting Th2
disease susceptibility; and, we provide support for the use ADAM10 inhibitors in treating
Th2 disease.
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Introduction
A disintegrin and metalloproteinases (ADAMs) are zinc dependent proteinases, which perform
ectodomain cleavage of transmembrane proteins. ADAM10 and ADAM17, or tumor necrosis
factor alpha (TNF) converting enzyme (TACE), are structurally related and share overlapping
substrates including TNF [1,2]. ADAM10 contributes to allergic disease being the principal
sheddase of CD23, the low affinity IgE receptor, which promotes IgE production [3,4] and is
increased in allergic patients’ sera [5]. In an experimental asthma model [4,6], ADAM10 inhib-
itor administration significantly attenuated airway hyperreactivity, suggesting that increased
ADAM10 activity predisposes to allergic disease.
The Th1/Th2 paradigm is attributed to differences in CD4+ T cell response and has been
studied extensively in both mice and humans. Allergic diseases are skewed towards a Th2 phe-
notype and classic Th1 (such as C57Bl/6 and SJL/J) and Th2-prone (such as Balb/c and A/J)
strains were characterized as high (Balb/c, A/J), intermediate (C57Bl/6), and low (SJL/J) IgE re-
sponders based on in vivo IgE production post immunization [7]. Whether B cells from Th1 or
Th2-biased mouse strains have intrinsic differences in ADAM10 and ADAM17 and if such dif-
ferences affect IgE production has never been elucidated.
In the absence of B cell ADAM10 (B-ADAM10) in C57Bl/6 mice (C57-ADAM10B-/-), a key
compensatory increase in ADAM17 and thus TNF shedding [8] results in aberrant B cell/T cell
localization, reduced germinal center formation, decreased follicular dendritic cell (FDC) mat-
uration, excessive collagen deposition, and increased high endothelial venule (HEV) formation
[8–11]. Furthermore, C57-ADAM10B-/- mice were less susceptible to airway hypersensitivity
induction, suggesting a specific role for B-ADAM10 in provoking allergic disease [6]. This phe-
notype is C57-ADAM10B-/- mice is not found, however, in Balb-ADAM10B-/- mice thus posing
a critical question about ADAM10 and ADAM17 regulation in different Th contexts. Herein,
we explore key differences between typical Th1 and Th2 prone strains with respect to
ADAM10, ADAM17, and TNF and in ADAM17 regulation following ADAM10 deletion.
We further extend our studies to allergic disease situations both in humans using active al-
lergic rhinitis patients and in mice by using a clinically relevant house dust-mite (HDM) airway
model. We investigate specifically whether intrinsic differences in B cell ADAM10 levels, inde-
pendent of Th bias, regulates allergy induction and severity and whether this regulation is asso-
ciated with modulation of B cell ADAM17 and TNF and associated changes in secondary
lymphoid follicular architecture.
Materials and Methods
Ethics Statement
All human studies were approved by the Virginia Commonwealth University IRB. Patients
were informed of the study and consented by Dr. Anne-Marie Irani using the approved IRB
survey: IRB #00870. Patients were described the IRB approved survey and then signed the
waiver enclosed. All animal care and experimental protocols were approved by Virginia Com-
monwealth University Institutional Animal Care and Use Committee and were in accordance
with NIH guidelines. Mice were sacrificed by isoflurane inhalation followed by cervical disloca-
tion. Anesthesia used for intranasal injections was mixed oxygen/isoflurane.
Mice
C57Bl/6 ADAM10B-/- (CD19-cre+) mice (C57-ADAM10B-/-) were generated [12] and back-
crossed to Balb/c (Balb-ADAM10B-/-) for 8 generations and compared to littermate controls
(CD19-cre-). A/J, SJL/J, C57Bl/6, and Balb/c WT were from Jackson Laboratories. All mice
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were 6–12 weeks when used. All animal care and experimental protocols were approved by
Virginia Commonwealth University Institutional Animal Care and Use Committee and were
in accordance with NIH guidelines.
Human studies
All human studies were approved by the Virginia Commonwealth University IRB. Sixteen
symptomatic allergic rhinitis patients and 16 controls were recruited for the study by Dr.
Anne-Marie Irani at VCU. Inclusion criteria included active allergic rhinitis symptoms and a
documented positive skin test or ImmunoCAP to an antigen as consented in IRB #00870 (S1
Fig Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood using
Ficoll, stained, and remaining PBMC underwent CD19 B cell selection using magnetic beads
(Miltenyi Biotec). B cells were cultured for 2 days (or 5 days for CD23 ELISA) with 200 ng/mL
human IL-21 (ATCC), 1 μg/mL anti-CD40 (Clone G28-5, ATCC), and 10 ng/mL rhIL-4
(R&D). Stimulated B cells were harvested, stained for flow cytometry, analyzed by qPCR, and
sCD23 determined by ELISA [13]. HDM Dermatophagoides pteronyssinus IgE was determined
by ImmunoCAP (Phadia, 14-4107-01).
Murine B cell culture and TNF ELISA
Positively selected B220+ splenic B cells (Miltenyi Biotec) were grown for 1–3 days in cultures
containing 1000 units IL-4 and 50 μg/mL LPS (E. coli 0111:B4, Sigma) or 1.25μg/mL purified
anti-mouse CD40 (Biolegend) [8]. Supernatants were analyzed for sTNF by ELISA
(eBioscience).
Murine HDM studies
C57Bl/6 WT, C57-ADAM10B-/-, Balb/c WT, and Balb-ADAM10B-/- mice were intranasally ex-
posed to 25μL saline or 15μg/25μL HDM extract (Greer Laboratories) (S2 Fig) [14]. Broncho-
constriction was assessed using Flexivent (Scireq, Montreal, QC, Canada) as previously
described [15]. Airway resistance (Rrs) was determined at increasing doses of methacholine (5,
10, 25 mg/ml) and presented as percent increase from PBS baseline. HDM specific IgE deter-
mined by ELISA as described [16]. Briefly, plates were coated with 20μg/mL HDM extract in
50mM carbonate buffer, blocked with SuperBlock (Thermo Scientific), detected using goat
anti-mouse IgE (Abcam), followed by addition of Streptavidin-HRP (Southern Biotechnolo-
gies), and color developed with tetramethylbenzidine + substrate (BD Biosciences). Reaction
was stopped with 1N H2SO4 and absorbance read at 450nm.
BALF cells were stained with APC-B220, APC-CD3, BV421-1A/1E, BV605-CD11c, and
PE-CCR3 (Biolegend) after FcR blockade with anti-mouse CD16/32 (2.4G2). Samples were ex-
amined on a BD Fortessa and analyzed with FCS Express, v. 4. using the gating strategy de-
scribed [17]. BALF supernatants were analyzed for MUC5AC protein by ELISA as described
[15]. Briefly, BALF was diluted and 75μL was incubated with 75μL carbonate buffer. Samples
were incubated overnight without a lid at 37°C then washed three times with PBS. Plates were
blocked, detected with anti-Muc5AC mouse monoclonal antibody (Pierce, 1:100), followed by
addition of goat anti-mouse IgG-HRP (Southern Biotechnologies,1:10,000), developed with
tetramethylbenzidine + substrate (BD Biosciences), stopped with 1N H2SO4, and absorbance
read at 450nm.
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Murine Lung histology
Five μm sections of formalin-fixed, paraffin-embedded murine lung tissue were stained with
hematoxylin and eosin (H&E) and Periodic acid-Schiff (PAS) (AML Laboratories, Inc. Balti-
more, MD) and photographed using Olympus-DP70 camera on Olympus-BX41 microscope.
Histopathologic evaluation of H&E stained lung sections from at least 4 mice per group was
performed by a pathologist in a blinded fashion using a semi-quantitative scoring system on a
Nikon Eclipse microscope. Peribronchiolar and perivascular inflammatory cellular infiltration
were scored separately as follows: 0, no or occasional cells; 1, few or loosely arranged cells; 2,
focal involvement of lung parenchyma with majority of airways or vessels having rings (partial
or complete) of inflammatory cells one cell layer deep; 3, patchy involvement of lung parenchy-
ma with majority of airways or vessels having rings (partial or complete) of inflammatory cells
two to four cell layers deep; 4, extensive involvement of lung parenchyma with majority of air-
ways or vessels having rings (partial or complete) of inflammatory cells more than four cell lay-
ers deep. Individual scores for peribronchiolar and perivascular inflammation were added
together for a total maximum score of 8.
qPCR and western blotting
Total RNA was extracted using TRIzol reagent (Invitrogen) and quantified by NanoDrop-100
spectrophotometer. Real-time quantitative PCR was performed with an iQ5 (Bio-Rad Labora-
tories) [8]. TaqMan quantitative PCR assays (Applied Biosystems, Life Technologies) were run
using primers/probes: TNF (Mm00443258 or Hs01113624), ADAM10 (Mm00545742 or
Hs00153853), ADAM17 (Mm00456428 or Hs01041915), 18s (Mm03928990), and GAPDH
(Hs02758991). Fold variation analyzed using delta-delta Ct (ΔΔCt) formula [18].
Proteins were assessed by western blot [8] using rabbit-anti-β-actin peroxidase (Sigma-Al-
drich) or anti-ADAM17 (Abcam) followed by HRP-anti-rabbit IgG and detected with Super-
Signal West Pico Chemiluminescent Substrate (Thermo Scientific).
Flow cytometry
Mouse B220+ B cells or human PBMC were blocked with 10 μg 2.4G2 or human FcR blocker
(Miltenyi Biotec), respectively. Human PBMC was stained with anti-human PE-CD19,
APC-CD14, or PE-CD3 (Biolegend). Mouse and human cells were washed, fixed, permeabi-
lized, blocked again, and stained with their respective antibodies: FITC-hADAM10 (R&D),
PE-mADAM10 (R&D) and/or rabbit-anti-ADAM17 (Abcam) followed by DyLight-649 anti-
rabbit IgG (Biolegend). Isotype control for hADAM10 is mouse IgG2b FITC (R&D), for
mADAM10 is Rat IgG2a PE (R&D), and for ADAM17 is rabbit IgG. Tyramide Signal Amplifi-
cation (Kit #26) was used for mouse B cell TNF staining as described [8]. Dead cells and aggre-
gates were excluded by scatter gating, examined on a BD Canto, and analyzed with FCS
Express, v.4.
Immunohistochemistry and confocal microscopy
Ten μm frozen mouse LN sections were dual and triple-labeled for FDCs (PE-anti-CD21/
CD35, Biolegend, 123410), B cells (Alexa-Fluor-647-anti-CD45R/B220, Santa Cruz Biotech-
nology, sc-19597- Alexa-Fluor-647), HEVs (anti-peripheral node addressin (pNAD), Biole-
gend, 120804), T cells (Anti-CD90.2/Thy-1.2-PE, Southern Biotech, 1750-09L), collagen-1
(Abcam, ab21286), and TNF (Abcam, ab34674). Instrumentation and quantitative assessment
of sections performed as previously described [8]. TNF labeling was enhanced using Fluoresce-
in-TSA (TSA Plus Fluorescein System, Perkin Elmer, NEL741001KT) [8].
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Statistical analysis
Normal distribution of data sets was determined using the Shapiro-Wilk normality test with
SigmaPlot 12.5. Furthermore, the mean and medians were close for data sets indicative of
normal distribution. Significance (p<0.05) was calculated using unpaired two-tailed Student
t tests (Figs 1–5) and one-way ANOVA with Tukey post-test (Figs 5 and 6) in GraphPad
Prism. Error bars represent SD; except in Fig 1A where error bars represent 95% confidence
interval.
Fig 1. Allergic patient B cells exhibit increased ADAM10 and sCD23 but decreased ADAM17 and TNF. (A) Total ADAM10 in naïve CD19+ B cells from
control (thin line, open dot) and allergic (bold line, black dot) patients; dot plot (right) shows percent of total B cells staining high in ADAM10 (grey gate).
Isotype control is shaded grey in histogram. (B,C) Total ADAM10 on naïve T cells (B) and monocytes (C). (D) sCD23 from control (open dot) or allergic (black
dot) supernatants. (E) Naïve B cells from 4 allergic and 4 control patients analyzed for ADAM10, ADAM17, and TNFmessage normalized to GAPDH.
Significance (*) indicates 2 fold change between allergic and control B cells for respective gene. (F) HDM specific IgE levels in sera of control (open dot) or
allergic (black dot) patients determined by ImmunoCAP. <0.35kuA/l considered a negative result. *p<0.05, **p<0.005, ***p<0.0005.
doi:10.1371/journal.pone.0124331.g001
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Results
Allergic patients exhibit increased B cell ADAM10, CD23, and IgE
Given the increased circulating sCD23 in the sera of allergic patients [5], we hypothesized that
actively allergic patients would exhibit increased B-ADAM10 compared to controls. Naïve B
cells from 16 allergic patients exhibited significantly increased B-ADAM10 compared to 16
controls (Fig 1A) by flow cytometric analysis. Contrastingly, T cells (Fig 1B) and monocytes
(Fig 1C) from allergic and control patients revealed comparable ADAM10 expression. Thus,
only B-ADAM10 expression served as an allergy-associated differential indicator.
Fig 2. Increased B-ADAM10 and decreased ADAM17 and TNF in Th2 biased strains.Naïve B220+ B cells (A, B) stained for total ADAM10 (A) or
ADAM17 (B) expression by flow cytometry. (C) TNF coexpression on 3 day stimulated (anti-CD40+IL4) B220+ B cells by TSA. (A,B,C) Bar graph represents
percent total B cells staining high in ADAM10 (A), ADAM17 (B), or TNF (C). (A,B,C) Balb/c (──)A/J (----), C57Bl/6 (▬▬▬), SJL (▪▪▪▪▪), respective isotype
control (shaded grey) in representative overlay (left); grey gate demonstrates high stained population. n = 8 per group, 3 independent studies. *p<0.05,
**p<0.005, ***p<0.0005. (D) TNFmessage from 3 day stimulated (anti-CD40 + IL4) B220+ B cells. Presented as fold change from C57Bl/6 WT. * signifies
2 fold change between C57Bl/6WT and the listedWT strain.
doi:10.1371/journal.pone.0124331.g002
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Furthermore, increased sCD23 in allergic B cell cultures indicated high ADAM10 activity in al-
lergic B cells (Fig 1D). B-ADAM10 message in allergic patients was increased nearly 5-fold,
while ADAM17 and TNF message were decreased 2-fold compared to controls (Fig 1E).
Given that increased B-ADAM10 leads to increased IgE production through CD23 cleavage
[4], we next compared serum antigen-specific IgE between allergic and control patients. We
were reliant on each patient self-reporting a specific antigen to which he/she was allergic in
order to perform an antigen specific ImmunoCAP [19]. Five of 16 allergic patients self reported
HDM sensitivity and ImmunoCAP demonstrated positive HDM specific IgE levels (>0.35
kuA/I) (Fig 1F). Five control patients, who are also quite likely exposed to HDM daily but do
not develop allergy, demonstrated negative ImmunoCAP results (<0.35 kuA/I) or very low lev-
els (0.41kuA/l) (Fig 1F). We next compared each individual patient’s HDM-specific IgE result
to his/her respective B cell ADAM10 expression (Table 1). In general, all control patients ex-
hibited very low or negative HDM specific IgE and low ADAM10 expression (< 25%)
(Table 1). As HDM specific IgE levels increased, B cell ADAM10 expression also increased in
Fig 3. B cell TNF and ADAM17 regulation in C57Bl/6 and Balb/c ADAM10B-/- (A10K0) andWT. (A) sTNF
or (B) mTNF from 3 day stimulated (LPS + IL4) B cell cultures; (B) Balb/c WT (black), Balb/c A10KO (red),
C57Bl/6 WT (green), and C57Bl/6 A10KO (blue) B cells. (C) Fold change (A10KO over WT) in relative TNF
message from naïve (white) or 3 day stimulated (anti-CD40+IL4) (black) B cells normalized to 18s. (D) Fold
change (A10KO over WT) in relative ADAM17 expression normalized to 18s for naïve (white) or 3 day
stimulated (black) B cells. (C,D) * signifies2 fold change between groups. (E) ADAM17 (~93kDa) and actin
(~42kDa) from 5 day stimulated (anti-CD40 + IL4) B cells (left) and band densitometry (right). KO = A10KO.
n = 9 per group, 3 independent studies. *p<0.05, **p<0.005.
doi:10.1371/journal.pone.0124331.g003
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Fig 4. Balb-ADAM10B-/- LN exhibit WT architecture unlike C57-ADAM10B-/- nodes.Naïve LN sections from C57Bl/6 and Balb/c WT and ADAM10B-/-; (A)
B cell (blue, B220), T cell (red, Thy1.2), and HEV (green, pNAD); (B) FDC reticula (red,CR1/2), collagen (green), and cortico-medullary junction (dotted line in
inset box); (C) TNF staining (green), B cell (blue, B220) follicle. (D) Average TNF staining intensity representing 12 follicle sections per group. Scale bar,
50μm. **p<0.005.
doi:10.1371/journal.pone.0124331.g004
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allergic patients. One allergic patient, however, had a lower HDM specific IgE result at 5.4
kuA/l, but demonstrated a high B cell ADAM10 level (69%) (Table 1). This patient, specifically,
reported multiple antigens to which he/she is allergic. Therefore, 5.4 kuA/l reflects only the
level of HDM specific IgE and is most likely lower than the total antigen specific IgE present in
the serum. Overall, Fig 1 and Table 1 demonstrates a correlation between increased serum anti-
gen-specific IgE and increased B cell ADAM10 in allergic patients.
Increased B-ADAM10 and decreased ADAM17 and TNF in Th2 prone
strains
Since B cell levels of ADAM10, ADAM17, and TNF mRNA expression were clearly different in
control and allergic patients; and allergy is a Th2-dominated disorder; we sought to confirm
our results in classic Th1 and Th2 prone mouse strains. Naïve B cells from Th2 prone Balb/c
and A/J expressed higher total ADAM10 (Fig 2A) and decreased total ADAM17 (Fig 2B) com-
pared to Th1 prone C57Bl/6 and SJL/J. Upon stimulation in vitro, B cells from the chosen Th1
prone strains expressed increased mTNF compared to the chosen Th2 prone strains (Fig 2C).
Furthermore, TNF message was lower in Th2 prone A/J and Balb/c mice compared to C57Bl/6
Fig 5. B-ADAM10 deletion attenuates bronchoconstriction and HDM specific IgE. (A) Airway resistance (cmH20.s/mL) with increasing doses of
methacholine (left); Balb-WT (──,), Balb-ADAM10B-/-(——,●), C57-WT (──,□), C57-ADAM10B-/- (——,■), Saline (──,●) presented as fold increase from
saline control. Bar graph (right) represents 25 mg/mL methacholine dose. (B) Percent macrophages (left) and eosinophils (right) from total BALF determined
by flow cytometry; Saline control (white), Balb WT (checkered), Balb-ADAM10B-/- (dotted), C57WT (slash), and C57-ADAM10B-/- (black). (C) HDM specific
IgE production. n = 7–9 per group, 3 independent experiments. All mice immunized with saline demonstrated comparable results. For simplicity, saline
represents Balb WTmice given saline. *p<0.05, **p<0.005, ***p<0.005.
doi:10.1371/journal.pone.0124331.g005
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WT by2 fold (Fig 2D). C57Bl/6 WT TNF expression was not significantly different from
SJL/J levels of TNF expression (Fig 2D). B cell ADAM10 in both Th1 prone-C57Bl/6 and Th2
prone-Balb/c strains increased following in vitro stimulation (S1 Table). However, Th2 prone
Balb/c maintained a consistently higher level of B cell ADAM10 even after equal stimulation
(S1 Table). This finding demonstrates that T cell help augments ADAM10 expression but does
Fig 6. B-ADAM10 deletion reduces cellular infiltration, goblet cell metaplasia, andmucus production in a strain dependent manner. (A) H&E stain
for lung tissue demonstrates peribronchiolar and perivascular inflammatory cellular infiltration (red box); 10x magnification, scale bar 200 μm. (B) Goblet cell
metaplasia determined by PAS stain; note dark pink mucin producing cells (black arrow) and alveolar epithelium thickness; 20x magnification, scale bar
100 μm. (C) Lung pathology score representing quantitation of peribronchiolar and perivascular inflammatory cellular infiltration on H&E stained lung
sections; 2 sections per mouse and at least 4 mice per group were assessed. (D) MUC5AC protein. n = 7–9 per group, 3 independent experiments. All mice
immunized with saline demonstrated comparable results. For simplicity, saline represents Balb WTmice given saline. *p<0.05, **p<0.005.
doi:10.1371/journal.pone.0124331.g006
B Cell ADAM10 in Th2-Biased Immune Responses
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not provide the mechanism by which B-ADAM10 is initially increased in Th2 prone over Th1
prone strains.
Differential ADAM17 and TNF in Balb-ADAM10B-/- compared to C57-
ADAM10B-/-
C57-ADAM10B-/- B cells exhibit a compensatory increase in ADAM17 expression and func-
tion resulting in excessive TNF cleavage, which provided the mechanism for the aberrant sec-
ondary lymphoid tissue architecture noted in these mice [8,9]. Given our results in Figs 1 and
2, we predicted that Th2 prone Balb-ADAM10B-/- B cells would exhibit reduced ADAM17 and
TNF compared to Th1 prone C57-ADAM10B-/- B cells, which may help to maintain WT lym-
phoid tissue architecture. Distinctively, sTNF production by Balb-WT and Balb-ADAM-10B-/-
B cells was comparable following in vitro stimulation (Fig 3A) unlike our previous report in
C57Bl/6 [8], which demonstrated significantly increased sTNF production by
C57-ADAM10B-/- B cells compared to WT in the same in vitro conditions. Furthermore,
mTNF in stimulated B cells is comparable between Balb-WT and Balb-ADAM10B-/- but re-
duced compared to C57-WT and even further reduced compared to C57-ADAM10B-/- (Fig
3B). Similarly to C57, Balb-WT and Balb-ADAM10B-/- express comparable TNF message in
the naïve state (Fig 3C). Upon stimulation, however, Balb-ADAM10B-/- B cells fail to signifi-
cantly increase TNF message above Balb-WT levels unlike C57-ADAM10B-/- B cells (Fig 3C).
Furthermore, C57-ADAM10B-/- B cells exhibit increased TNF message compared to Balb-
ADAM10B-/- (Fig 3C).
Given that TNF levels were reduced in Balb-ADAM10B-/- compared to C57-ADAM10B-/- B
cells, we next compared the levels of ADAM17 protein and message. Unlike C57Bl/6,
ADAM17 message in naïve Balb-WT and Balb-ADAM10B-/- B cells was comparable and in-
creased to 2-fold higher expression in Balb-ADAM10B-/- B cells upon stimulation (Fig 3D).
C57-ADAM10B-/- B cells exhibited increased ADAM17 protein (Fig 3E) compared to
C57-WT, but also compared to Balb-WT and most interestingly, Balb-ADAM10B-/-. Further-
more, ADAM17 protein was comparable between Balb-WT and Balb-ADAM10B-/-, which is
consistent with TNF production in Fig 3A (Fig 3E)
Unlike C57-ADAM10B-/-, Balb-ADAM10B-/- exhibit normal secondary
lymphoid tissue architecture
Given the marginal changes in TNF and ADAM17 (Fig 3) in Balb-ADAM10B-/- compared to
our previous report in C57-ADAM10B-/- [8], we hypothesized Balb-ADAM10B-/- lymph nodes
would maintain WT architecture. Indeed, Balb-ADAM10B-/- exhibited comparable primary
follicular characteristics to C57-WT and Balb-WT, including normal B cell/T cell
Table 1. Increased HDM specific IgE correlates with increased B cell ADAM10 expression.
Control Allergic
HDM Speciﬁc IgE (kuA/l) Percent CD19+ADAM10high HDM Speciﬁc IgE (kuA/l) Percent CD19+ADAM10high
<0.35 13 5.4 69
<0.35 18 12.8 48
<0.35 22 15.0 51
<0.35 25 18.0 60
0.41 15 22.0 72
Direct comparison of individual patient’s HDM speciﬁc IgE determined by ImmunoCAP and B cell ADAM10 expression determined by ﬂow cytometry.
doi:10.1371/journal.pone.0124331.t001
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compartmentalization (note the lack of B/T compartmentalization in the C57-ADAM10B-/-
compared to other groups) (Fig 4A), number and size of HEVs (Fig 4A), FDC reticular devel-
opment (note minimal CD21+ FDC in C57-ADAM10B-/-) (Fig 4B, inset Fig 4B), and collagen
deposition (note collagen is normally sparse but is increased in C57-ADAM10B-/-) (Fig 4B).
Furthermore, TNF labeling (boxed regions of Fig 4C) demonstrated that C57-ADAM10B-/- fol-
licles displayed the highest TNF intensity compared to C57-WT, Balb-WT, and Balb-
ADAM10B-/- (Fig 4C), with the latter groups all having comparable TNF staining (Fig 4C),
which is quantified in Fig 4D. These results provide further support to the mechanism underly-
ing the aberrant lymphoid tissue architecture in C57-ADAM10B-/- mice and demonstrate the
inherent difference in B cell ADAM10 and ADAM17 regulation in Th1 vs. Th2 prone mice.
High B-ADAM10 level in the context of a Th2 environment allows optimal
induction of allergic airway disease symptoms
C57Bl/6 WT exhibit a decreased response to mouse lung inflammation models compared to
Balb/c including airway bronchoconstriction and IgE production, however, these findings
have never been linked to B-ADAM10 levels, specifically [8,20,21]. Our results thus far indicate
that Th2 prone mice and humans, whose B cells are known to produce excess IgE, exhibit in-
creased B cell ADAM10 even in a naïve, non-stimulated state. After stimulation with anti-
CD40/IL4, B-ADAM10 levels increased more dramatically in Th2 prone strain B cells as well.
Therefore, we next sought to compare the consequences of B cell ADAM10 level in the context
of a Th1 or Th2 immune-environment on airway hypersensitivity induction following HDM
challenge, specifically with regards to IgE production. The groups considered included: B cell
ADAM10 high, Th2 prone (Balb/c WT); B cell ADAM10 low, Th1 prone (C57 WT); B cell
ADAM10 deleted, Th2 prone (Balb-ADAM10B-/-); and B cell ADAM10 deleted, Th1 prone
(C57-ADAM10B-/-). When each group was treated intranasally with saline, all disease parame-
ters were similar (not statistically different). For clarity, saline treated Balb WT was chosen as
the representative saline group in Figs 5 and 6.
Th2 prone, B-ADAM10 high Balb WT exhibit the most severe induction of lung inflamma-
tion following HDM challenge, including increased bronchoconstriction (Fig 5A) and exten-
sive peribronchiolar and perivascular inflammatory cellular infiltration in lung tissue (boxed
regions in Fig 6A and 6C). Similarly, Balb WT exhibit the highest goblet cell metaplasia as indi-
cated by the intense pink staining mucin (arrows in Fig 6B) and mucus (MUC5AC protein)
production (Fig 6D). Furthermore, the thickness of the alveolar epithelium (Fig 6B) is greatest
in the Balb/c compared to other groups with the C57-ADAM10B-/- being reflective of saline
controls. In accordance with our main hypothesis that increased B cell ADAM10 lends to in-
creased IgE production, Balb WT exhibited the highest HDM-specific IgE (Fig 5C) as well.
When ADAM10 is deleted from B cells but remains in the context of a Th2 environment in the
Balb-ADAM10B-/-, bronchoconstriction (Fig 5A), goblet cell hyperplasia (Fig 6B), and mucus
production (Fig 6D) are reduced significantly from Balb WT and are quite similar to the Th1
prone, B-ADAM10 low C57-WT. Furthermore, HDM-specific IgE (Fig 5C) is reduced from
Balb WT levels demonstrating the critical importance of B cell ADAM10 for IgE production
even in a Th2 prone environment. Lastly, B-ADAM10 deletion in the context of a Th1 environ-
ment (C57-ADAM10B-/-) provides the least suitable context for allergic airway disease induc-
tion. Thus, as indicated previously, C57-ADAM10B-/- mice exhibited bronchoconstriction (Fig
5A), cellular infiltration of lung tissue (Fig 6A and 6C), goblet cell metaplasia (Fig 6B), and
mucus production (Fig 6D) similar to saline control. While the HDM-specific IgE ELISA was
not sensitive enough to detect differences between saline, C57-WT, and C57 and Balb-
ADAM10B-/-, it does indicate the importance of both ADAM10 and strain background in IgE
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production as both the Balb-ADAM10B-/- and C57-WT demonstrated significantly reduced
HDM-specific IgE production compared to Balb WT (Fig 5C). Furthermore, B-ADAM10 dele-
tion from Balb or C57 fails to reduce eosinophilic recruitment in BALF, but it appears to be a
strain dependent phenomena as Balb/c mice regardless of B cell ADAM10 presence had in-
creased eosinophils compared to C57 WT and C57-ADAM10B-/- (Fig 5B).
Discussion
Compelling evidence, herein, demonstrates that B-ADAM10, ADAM17, and TNF are differen-
tially regulated in Th1 and Th2-dominated immune responses and directly influence host sus-
ceptibility to allergy and IgE production. We demonstrate that Th2 prone mouse strains (Fig 2)
and humans (Fig 1) exhibit increased B cell ADAM10 and IgE (Fig 1F, Table 1 and Fig 5C),
while concomitantly having reduced ADAM17 and TNF (Fig 3). With regards to mouse
strains, we compared to C57-ADAM10B-/- B cells to Balb-ADAM10B-/- and found that Th en-
vironment is critical for ADAM17 and TNF regulation as Balb-ADAM10B-/- are less adept at
increasing ADAM17 and thus TNF cleavage following ADAM10 deletion (Figs 3 and 4) [8].
WT levels of TNF production by Balb-ADAM10B-/- B cells allows for maintenance of proper
secondary lymphoid tissue architecture and provided further evidence to the mechanism un-
derlying abnormal architecture characteristics in C57-ADAM10B-/- nodes (Fig 4) [8].
A critical question is whether B cell ADAM10 levels is strictly determined by T cell help or
is an inherent characteristic of B cells from Th1 or Th2 prone strains. The answer is both. T
cell help as demonstrated by in vitro culture with equal concentrations of anti-CD40/IL4 shows
that B cell ADAM10 increases in both C57 and Balb WT B cells following stimulation (S1
Table and Fig 2). Thus, T cell help augments ADAM10 expression. Importantly, however, Balb
WT B cells exhibit increased ADAM10 in the naïve state and even more dramatically increased
ADAM10 after anti-CD40/IL4 stimulation compared C57-WT B cells (S1 Table). This finding
indicates an innate difference between their B cells that affects their sensitivity to T cell mediat-
ed ADAM10 induction.
Next, regulation of ADAM17 and its ligand, TNF, in different Th contexts was analyzed.
C57-WT B cells demonstrated increased ADAM17 in naïve B cells and increased TNF expres-
sion following in vitro stimulation compared to Balb-WT B cells (Fig 2). These B cell differ-
ences in the classic Th1 and Th2-biased strains extended other strains of mice as well. For our
studies, we used to SJL/J and C57Bl/6 as our Th1 prone strains and A/J and Balb/c as our Th2
prone strains (Fig 2). Furthermore, Th context is critical for understanding the difference in
ADAM17 and TNF regulation following B cell ADAM10 deletion as shown in Fig 3, as Balb-
ADAM10B-/- B cells fail to increase ADAM17 and TNF production, thus permitting WT archi-
tecture maintenance (Fig 4). Our evidence suggests that regulation of B-ADAM10 and
ADAM17 is both determined by Th context (e.g. T cell help) but also on inherent differences
in B cell responsiveness.
In agreement with the clinically relevant HDMmodel used herein, OVA-induced airway
hypersensitivity was also reduced in C57-ADAM10B-/- [6]. In this study using a HDMmodel,
we directly compare C57 and Balb ADAM10B-/- mice and both experienced significantly less
bronchoconstriction, goblet cell metaplasia, mucus, and HDM-specific IgE production (in
Balb/c) compared to their respective WT strain (Figs 5 and 6). Importantly, however, Balb-
ADAM10B-/- mice had lung inflammation parameters comparable to WT-C57 mice, while
C57-ADAM10B-/- had the lowest disease induction. Furthermore, while clinically relevant fea-
tures of human asthma including antigen-specific IgE, mucus, and airway resistance were
clearly ADAM10 dependent, eosinophil infiltration was strain dependent only (Fig 5). This
finding does not detract from the potential use of ADAM10 inhibitor therapy, however,
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because blockade of eosinophil infiltration alone fails to reduce asthma related symptoms in
most allergic patients [22,23]. Overall, the data indicates that B-ADAM10 plays an important
role in this Th2 disease model with the highest ADAM10 expression indicating worst sympto-
mology. While the mechanism by which ADAM10 levels influence Th2 disease is unknown, a
candidate mechanism could be that ADAM10-mediated CD23 shedding increases IgE produc-
tion, thus enhancing IgE cross-linking and mast cell degranulation [4]. If further validated in a
larger human cohort study, ADAM10 level could serve as a potential indicator of the direction-
ality or strength of a Th1 or Th2 response, with high ADAM10 level indicating a propensity to-
ward enhanced Th2 responsiveness with excess IgE production.
Our data in mouse strains was validated by our findings in allergic patients (Th2 prone)
who demonstrated increased B cell ADAM10 and reduced B cell ADAM17 and TNF produc-
tion (Fig 1). Together this suggests that B cell-ADAM10 screening could effectively stratify al-
lergic from non-allergic patients potentially for their susceptibility to more severe disease. An
appropriate, cost-effective means to perform this task is used herein: flow cytometric analysis
of ADAM10 levels on peripheral blood CD19+ B cells obtained from a minimally invasive ve-
nous puncture. Furthermore, while ADAM10 screening could be a critical diagnostic tool,
ADAM10 inhibition therapy also stands to be the only mechanism by which to inhibit the ini-
tial step in the allergic cascade: IgE production. We demonstrate, herein, that B cell ADAM10
deletion reduces antigen-specific IgE production (Fig 5C). Consequently, ADAM10 inhibitors
have the potential to provide anti-allergic prophylaxis when locally administered particularly
to atopic patients with high B-ADAM10.
Allergic patients with increased B-ADAM10 concomitantly had reduced B cell ADAM17
and TNF, which could also provide mechanistic insight into their enhanced IgE production.
Increased B cell TNF production, as seen in aging B cells, limits antibody production, suggest-
ing a potentially protective role of ADAM17 and TNF from induction of an allergic phenotype
[24]. Our findings, overall, suggest that allergy-prone B cells display an ADAM10hi/
ADAM17lo/TNFlo phenotype, with greater risk of atopic manifestations in Th2-biased envi-
ronments. Our results are an advance in elucidating the key role of ADAM10 in allergy patho-
genesis, and provide a novel approach to the diagnosis, prognosis, and treatment of
atopic disorders.
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